Back HCV Treatment

AASLD 2016: Non-Adherence Is Most Important Risk Factor for Sofosbuvir/Ledipasvir Failure

Research carried out by researchers at Mount Sinai Medical Center in New York found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C. The main reasons cited for non-adherence were failing to take medication as prescribed and hospitalization, according to a report at the 2016 AASLD Liver Meeting in Boston earlier this month.

alt

Read more: